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and items. Feedback on the questionnaire was also obtained from the  
patient interviewers, clinical experts and a translation expert. The conceptual 
framework and questionnaire were subsequently revised. RESULTS:  
The conceptual framework represents functional reading independence  
as a unidimensional concept. Eleven functional reading activities have a  
direct effect on functional reading independence: 1) reading written print; 2) 
reading to pay bills or write a check; 3) reading in order to take medicine; 4) 
reading instructions; 5) reading labels; 6) reading to play games; 7) reading to 
make or receive a telephone call; 8) reading words or numbers on the screen 
while watching television; 9) reading when using a computer; 10) reading street 
signs; and 11) reading signs for directions. The process of performing each 
functional reading activity may be completely independent, or may involve the 
use of vision aids, behavior changes to accommodate vision problems, and/or 
receiving help from another person. CONCLUSIONS: To our knowledge, this is 
the first conceptual framework specifically representing functional reading 
independence from the perspective of patients with GA. The conceptual 
framework may evolve once empirical evidence is available. The questionnaire 
based on the conceptual framework is currently being tested in a Phase II clinical 
trial.  
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OBJECTIVES: Wet Age-related Macular Degeneration (wAMD) is one of the major 
causes of visual impairment in Japan. However the patient burden from wAMD 
has not been widely reported. The objective of this study was to characterize 
how Japanese wAMD patients are affected by the disease. METHODS: This is a 
multi-site observational study across Japan on wAMD patients who have 
received medical treatment during the past 12 months. Collected patient-
reported outcome measures included Quality of Life using the National Eye 
Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) and depression scale 
by the Geriatric Depression Scale-Short Version-Japanese (GDS-S-J). Patients also 
reported on treatment satisfaction, caregiver assistance, and wAMD-associated 
comorbidities. RESULTS: Interim data for 211 patients are reported here; 97.2% of 
patients were 60 years of age and over. The mean score of NEI-VFQ-25 was 
68.19±17.84 and General Vision (45.78±18.07) was the lowest among 12 sub-
domains; 11.4% of patients had a score of 6 or above in GDS-S-J, indicating mild 
depression. A total of 38.4% and 45.5% of patients were dissatisfied with their 
treatment in terms on vision improvement and the time it takes for the 
treatment to work, respectively. A total of 10.4% of patients needed assistance 
with their daily tasks, but of those, only 4.7% had a caregiver to help them day-
to-day. 1.9% used paid services at home with the average of 1.3±0.47 hours per 
week; half of these patients used yearlong service and the rest used 6 months 
only; 5.9% of patients visited other doctors because of a fall which was related to 
their vision impairment. CONCLUSIONS: Our analyses showed that 38-45% of 
patients were dissatisfied with their current treatment. Very few patients who 
required assistance were able to have a caregiver to help them day-to-day. Paid 
services were also barely utilized.  
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OBJECTIVES: Manufacturers underestimate the time till reimbursement in the 
US for dermatology products and procedures. The purpose of this study was to 
examine the factors influencing time to reimbursement for different products 
and procedures and to identify strategies for ensuring optimal reimbursement 
status and CPT code valuation for such products, including consideration of the 
appropriate distribution channel. METHODS: The study involved 25 interviews 
with commercial medical and pharmacy directors, specialty pharmacy 
distributors, dermatologists and dermatology office managers. Interviews 
focussed on the perceptions and experiences of the interviewees in the 
prescribing of, and reimbursement for, new dermatology products and 
procedures. An analysis of historical coding evaluations for dermatological 
procedures was conducted and the challenges in building a valuation that is 
commercially viable were identified. RESULTS: Interviewees had multiple 
experiences of lacking the appropriate codes to secure reimbursement for the 
use of new dermatology products and procedures. These experiences have 
resulted in a situation where initial uptake of new products is out of line with 
the expectations of manufacturers. The process for informing the valuation of 
codes was considered to be highly politicised, with a need for extensive 
investment in supporting the case for the relative value units of a procedure. 
“Buy and bill” distribution routes were considered to be unsatisfactory from the 
point of view of dermatologist offices based. CONCLUSIONS: Manufacturers of 
new dermatology products that require the use of a procedure need to carefully 
consider their strategy for ensuring a reimbursement status and distribution 
route that enables dermatology offices to be reassured in using their product. A 
lack of planning may result in a total lack of uptake even for products that are of 
recognised clinical benefit.  
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OBJECTIVES: Ustekinumab is dosed at 45mg or 90mg (patient weight-dependent) 
in moderate-to-severe plaque psoriasis. The study objective was to assess 
observed increases (step-up from 45mg to 90mg) or decreases (step-down from 
90mg to 45mg) in ustekinumab dosing. METHODS: Truven Health MarketScan® 
Commercial and Medicare Supplemental databases were utilized to evaluate 
patients with: 1 ustekinumab index medical/pharmacy claim (09/25/2009-
10/31/2010); age ≥18 years at index; ≥ 6 months pre-index continuous enrollment; 
and ≥1 psoriasis diagnosis code (696.1) on or pre-index. Step-up and step-down 
dosing events and distribution of subsequent doses at each fill (doses 2-4) were 
assessed based on index dose received. Time to step-up or step-down was 
reported in days. RESULTS: Of 1,000 psoriasis patients receiving ustekinumab, 
step-up and step-down dosing events at anytime were evident in 9.9% (n=99) and 
6.8% (n=68), respectively. Median (mean±SD) time to step-up from index dose 
was 119 (113±76) days. Median (mean±SD) time to step-down from index dose 
was 49 (69±52) days. Of patients with step-up events, 37.4% returned to their 
original 45mg dose after step-up (mean=66 days). Of patients with step-down 
events, 39.7% returned to their original 90mg dose after step-down (mean=158 
days). Proportion of 45mg use by index 90mg patients spanned 6.1%-7.8% across 
doses. Proportion of 90mg use by index 45mg patients spanned 1.4%-16.8% 
across doses. CONCLUSIONS: In this observational study, <10% of psoriasis 
patients receiving ustekinumab had evidence of step-up/step-down dosing 
events at anytime. Over 1/3 of patients with either event returned to initial dose. 
Mean time to step-up was longer than mean time to step-down from initial dose 
by approximately 6 weeks. Step-up patients returned to lower initial dosing in a 
shorter period of time compared to step-down patients returning to higher initial 
dosing. Step-up/step-down dosing should be explored further in the context of 
weight, effectiveness, and safety.  
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OBJECTIVES: The aim of this study was to assess the annual health insurance 
reimbursement of dental health service in counties and regions of Hungary. 
METHODS: The assessment base of the study was the annual reports of National 
Health Insurance Fund Administration (OEP). Only the data collected from the 
services in contractual relationship with the OEP and delivered between 2008 
and 2011 were evaluated. Our study covers primary, outpatient and hospital 
dental care.We analyzed the following indicators: number of cases(patients) per 
100 inhabitants, number of intervention (procedures) per 100 inhabitant, 
intervention per case, and reimbursement per intervention. RESULTS: Dental 
care was supplied by 3366 general and specialist dental care services at the end 
of 2011. The average number of cases per 100 inhabitants was 71 and varied 
between 55-95 in different counties. The average number of interventions per 
100 inhabitants was 199 and varied between 149-268 in different counties. The 
average number of interventions per case was 2.8 (2.56-3.13). The average 
reimbursement per intervention showed also significant differences among the 
counties (1018-1217) with an average of 1122 Hungarian Forint per case. Due to 
the progressive dental care system in those counties were university dental 
school can be found, the utilization of dental services is higher than in counties 
without dental school. CONCLUSIONS: Within the period under investigation, 
the health insurance reimbursement of dental care showed significant 
differences among counties and regions of Hungary. The presence of dental 
school is an important predictive factor for higher than national average 
utilization of dental services.  
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OBJECTIVES: Actinic keratoses are characterized by dysplastic epidermal lesions 
that occur in pale-skinned individuals chronically exposed to intense sunlight. It 
is one of the most commonly treated skin conditions but its prevalence in the 
Brazilian population is still unknown. The objective of this research is to describe 
the profile of the patients diagnosed with AK in São Paulo city. METHODS: A two 
months health survey was performed in the city of São Paulo in which 10 
dermatologists registered the profile of the patients diagnosed with actinic 
keratosis. RESULTS: The dermatologists saw 4961 patients in two months, 5,4% 
(269 patients), were diagnosed with AK (58% women). The mean age of the 
patients was 65 years old. 42% informed a family history of AK and 21% history 
of nonmelanoma skin cancer. Among the patients 80% of the participants 
belonged to the two initial categories of the Fitzpatrick Scale. 39% of the lesions 
were hyperkeratotic and the most common localizations of the lesions were face 
(35%) and the upper extremity (26%). Seventy-one percent of the patients were 
treated with surgical destruction of the lesions (chemical cautery, cryotherapy, 
electrocautery) and just 29% were prescribed to administer topical therapy (5-
fluourouracil, imiquimod, retinoic acid). CONCLUSIONS: The prevalence of 
actinic keratosis in this sample is 5,42%. The most affected sites were face and 
